Court Sets Terms For Pfizer Damages Over Axed Lyrica IP
The money the National Health Service and generic drug companies can claim back from Pfizer over an invalidated epilepsy drug patent should be assessed based on how much money they would...To view the full article, register now.
Already a subscriber? Click here to view full article